|
Apr 15
|
Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook
|
|
Mar 14
|
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
|
|
Feb 24
|
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
|
|
Feb 21
|
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 21
|
Intra-Cellular: Q4 Earnings Snapshot
|
|
Feb 21
|
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
|
|
Jan 19
|
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally
|
|
Jan 19
|
Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’
|
|
Jan 17
|
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
|
|
Jan 15
|
J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns
|
|
Jan 15
|
J&J’s Top Rating at Risk Because of Intra-Cellular Deal
|
|
Sep 6
|
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
|
|
Sep 5
|
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
|
Aug 28
|
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
|
|
Jul 24
|
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
|
|
Jul 9
|
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
|
|
Jun 19
|
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
|
|
Jun 19
|
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
|
|
Jun 18
|
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
|
|
Jun 18
|
Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
|